Tag: cardiology

Posted on

Bulgarian Society of Cardiology’s journal accepted by Scopus

Following rigorous evaluation at Scopus – one of the world’s most comprehensive literature and citation databases – the official journal of the Bulgarian Society of Cardiology has been accepted, reports ARPHA Platform’s Indexing team.

Amongst the criteria Bulgarian Cardiology has successfully covered in order to prove as a journal that makes a significant and valuable contribution to the scientific community, are immaculate peer review and editorial processes, a good and consistent yearly publication volume, high-quality and user-friendly website and infrastructure, well-pronounced internationality and inclusivity, and considerable readership and citation rates.

The news means that all content published in Bulgarian Cardiology since 2019 will soon be discoverable and accessible from the worldwide popular corpus of scientific publications.

Further, these papers and their citations by authors in other Scopus-indexed journals will be mapped and counted, in order to calculate the journal’s Scopus CiteScore. According to Scopus, Bulgarian Cardiology will be benchmarked against 367 journals in the Cardiology category (data from SCIMAGO, retrieved in June 2023).

Traditionally, the yearly updated journal metric is released in June. To come up with the CiteScore, Scopus counts the citations of five peer-reviewed publication types  (i.e. research /  review / conference / data papers and book chapters) received in the last four complete years, before dividing the number by the same document types published during this period. 

The CiteScore formula explained using 2020 values as an example. See more in the CiteScore Journal Metric – FAQs.

Additionally, Bulgarian Cardiology will be making use of another quite unique metric by Scopus: the CiteScoreTracker. It uses the same formula as in the CiteScore to calculate the current publication/citation performance of a journal based on the data available by the beginning of each month. So, a journal receives a new Scopus CiteScoreTracker value each month, which serves as a preliminary forecast for the next Scopus CiteScore.

***

The Bulgarian Cardiology journal was launched in 1995 as the official scholarly outlet for the Bulgarian Society of Cardiology. Ever since, it has been serving as a forum to bring together the cardiology community within the country and beyond.

In 2020, Bulgarian Cardiology signed with Pensoft to move its journal to the scientific publisher’s ARPHA Platform, in order to modernise the academic outlet and provide its authors, readers and editors with a user-friendly environment where they can submit, revise, publish and permanently archive their work.

Back then, the Bulgarian Cardiology became the first ARPHA-powered journal to make use of the platform’s top-to-bottom bilingual publishing solution, which included a bilingual website and the option for authors to publish their work either in Bulgarian and English, or in English-only. 

Further, the Society took advantage of many human-provided services, including assistance in journal indexing. Additionally, the ARPHA website development team led the major revamp of the Bulgarian Society of Cardiology with the intention to align it with the new journal website.  

________

For news from & about ARPHA and the journals using the platform, you can follow us on Twitter and Linkedin.

Posted on

Interventional Cardiology Forum to publish on ARPHA in two languages

The Bulgarian Society of Interventional Cardiology’s journal Interventional Cardiology Forum now boasts an improved publishing infrastructure after moving to the technologically advanced ARPHA Platform, developed by scholarly publisher and technology provider Pensoft. This is the second cardiology journal to move on to ARPHA, after Bulgarian Cardiologydid so last year.

The official organ of The Bulgarian Society of Interventional Cardiology (BulSIC), Interventional Cardiology Forum popularizes scientific achievements in the rapidly developing, highly innovative field of interventional cardiology, which deals specifically with catheter-based treatment of heart diseases and including diagnosis and treatment of coronary artery disease, vascular disease and acquired structural heart disease. The journal provides a platform for the presentation of personal experience, ideas, discussions, and new techniques, devices and materials for catheterization laboratories.

Opting for ARPHA’s white-label solution, Interventional Cardiology Forum will benefit from ARPHA’s services while publishing under BulSIC’s branding and imprint. The journal is already enjoying a brand-new, user-friendly website under Pensoft’s scholarly publishing platform. Furthermore, it takes advantage of ARPHA’s signature fast-track publishing system, which offers an end-to-end solution from submission to publication, distribution and archiving. Providing a synergic online space for submission, reviewing, editing, production and archiving, ARPHA ensures a seamlessly integrated workflow at every step of the publishing process.

Interventional Cardiology Forum is the third journal in ARPHA’s universe to opt for bilingual publishing after Bulgaria’s National Cardiac Society’s Bulgarian Cardiology and Moscow State University’s Population and Economics. At Interventional Cardiology Forum, authors can publish their papers in either Bulgarian or both Bulgarian and English, where bilingual papers are displayed in both languages side by side.

Posted on

Bulgaria’s National Cardiac Society pioneers ARPHA’s top-to-bottom bilingual publishing

The first 2020 issue of the society’s bilingual journal is already online on a brand new and user-friendly website

(Прочетете на български тук)

This month, ARPHA Platform welcomed the fourth medical academic journal to its portfolio: Bulgarian Cardiology („Българска кардиология”), the official publication venue of the Bulgarian National Cardiac Society since 1995. The Society is a member of the European Society of Cardiology. 

With its first 2020 issue, Bulgarian Cardiology pioneers the Bulgarian-English bilingual publishing solution from ARPHA, the open-access scholarly publishing platform, developed by the publisher and technology provider Pensoft. Thanks to this, authors will be able to publish their papers either in Bulgarian, or in Bulgarian and English. In the latter case, the article will be displayed in both languages side by side, as exemplified in the paper “Novel approaches to treat resistant hypertension” by Dr Alexandra Cherneva (Acibadem City Clinic – Cardiovascular center, Bulgaria) and Prof Ivo Petrov (Sofia University and Acibadem City Clinic – Cardiovascular center, Bulgaria).

“Novel approaches to treat resistant hypertension”, a research paper by Dr Alexandra Cherneva and Prof Ivo Petrov, published in the latest issue of Bulgarian Cardiology, available in both Bulgarian and English
(DOI: 10.3897/bgcardio.26.e52712)

For non-Bulgarian speaking authors, who submit their manuscript in English, the journal provides translation to Bulgarian, so that the published article is also available in both languages. In the latest issue, this is exemplified by the Editorial piece “Atrial fibrillation: Importance of real world data from regional registries. A focus on the BALKAN-AF registry”, authored by the international team of Dr Monika Kozieł, Prof Gregory Y. H. Lip and Dr Tatjana S. Potpara.

Having already acquired its own glossy and user-friendly website provided by ARPHA, Bulgarian Cardiology also takes advantage of the platform’s signature fast-track, end-to-end publishing system, which is to benefit all journal users: authors, reviewers and editors alike. In addition, the published content enjoys automated export of data to aggregators, as well as web-service integrations with major global indexing and archiving databases.

The first issue of Bulgarian Cardiology was published in 1995 to provide a scholarly outlet for the Bulgarian Society of Cardiology. Ever since then, it has been serving as an essential forum to bring together the cardiology community in the country. Its aim is to publish both the academic achievements of the Bulgarian medical experts and the key practical guidelines of the European Society of Cardiology.  

Bulgarian Cardiology accepts for publication research and review articles, clinical cases, editorials, letters to the Editor, European Society of Cardiology guidelines, announcements from the Bulgarian Society of Cardiology and materials presented at their meetings, and others. 

“It’s a pleasure to all of us at ARPHA to welcome the Bulgarian Society of Cardiology’s journal. It’s a fantastic win-win situation for both parties: while we managed to customise and provide the necessary services the Society asked us for, they offered us the opportunity to further push our capabilities and know-how, in order to launch our first top-to-bottom bilingual publishing solution,”

says Prof. Lyubomir Penev, founder and CEO at ARPHA and Pensoft.

The journal will continue to be published also in print with four issues a year.

***

Visit the journal’s website at https://journal.bgcardio.org/.

Posted on

New promising compound against heart rhythm disorders and clogged arteries

The pharmacological agent outperforms current drugs in most of cases, show multiple experiments

A new pharmacological agent demonstrates promising results for the prevention of a wide range of heart rhythm disorders, including both cardiac and brain injury-induced arrhythmias. Furthermore, the compound (SS-68) demonstrates significant activity in conditions of reduced blood flow to the heart caused by obstructed arteries.

The study, conducted by a research team led by Dr Saida Bogus of the Kuban State Medical University in Russia, is published in the open-access journal Research Results in Pharmacology.

Each year, more than 17 million people from around the globe (mostly Europe and the USA) die of cardiovascular diseases and related complications, according to the World Health Organization. In Russia, about 3 out of 1,000 people suffer from the most common and malignant heart rhythm disorder: atrial fibrillation (AF), where the count is expected to at least double in the next 30 years. While sometimes lacking symptoms, atrial fibrillation could generally be recognised by a racing, irregular heartbeat, dizziness, fatigue, shortness of breath and chest pain, thereby largely compromising the quality of one’s life. The disorder could also lead to various complications, including dementia, stroke and heart failure.

Currently, the drugs administered to AF patients have major deficiencies, including narrow therapeutic windows, which means that even minimal imprecision in the dosage could result in unacceptable toxicity. Hence, patients need to be closely monitored and have their doses adjusted on a regular basis.

In their study, the team turned to the aminoindole derivatives to look for an alternative compound. This chemical group has already shown a significant potential in terms of cardio-pharmacological activity.

Having tested the SS-68 compound on multiple occasions in different animals, the researchers report that it has a pronounced antiarrhythmic effect and is able to bring the electrical activity of the heart back to normal and, in most cases, outperforming the reference drugs used in clinical practice: amiodarone, lidocaine, aymaline, ethacizine, etmozine and quinidine anaprilin.

Further, in brain injury-induced arrhythmias, the compound was found to reduce the episodes of epilepsy. It was also observed to have a positive effect in clogged blood vessels where it is reported to have successfully increased the coronary blood flow. In addition, the compound managed to decrease the area of necrosis in the heart tissue caused by a heart attack.

“To date, there have been significant achievements of Russian and foreign pharmacologists, chemists and clinicians in creating and introducing into the practical medicine a number of antiarrhythmic drugs different by their chemical structure, nature, spectrum, activity and mechanism of action; nevertheless, one of the most important tasks of modern pharmacology is searching for and developing new highly active substances of the corresponding action,” explain the scientists.

“Special attention should be paid to an in-depth study of the molecular mechanisms of action of this compound,” they conclude.

A paper looking further into the molecular mechanisms of the antiarrhythmic action of SS-68 prepared by the same research team is currently in press with Research Results in Pharmacology.

###

Original source:

Bogus SK, Galenko-Yaroshevsky PA, Suzdalev KF, Sukoyan GV, Abushkevich VG (2018) 2-phenyl-1-(3-pyrrolidin-1-il-propyl)-1 H-indole hydrochloride (SS-68): Antiarrhythmic and cardioprotective activity and its molecular mechanisms of action (Part I). Research Results in Pharmacology 4(2): 133-150. https://doi.org/10.3897/rrpharmacology.4.2859

 

###

 

Research Results in Pharmacology is one of the journals hosted on ARPHA through the platform’s white-label publishing solution.